CAS No.: 2139348-60-8 Cat No.: BP-100018 Purity: ≥98%4.5
Pomalidomide-PEG1-CO2H is a high-quality E3 Ligase Ligand-Linker Conjugate designed for targeted protein degradation research in the field of PROTAC (Proteolysis Targeting Chimera) drug development. This compound features a pomalidomide-based ligand for recruiting the CRBN (cereblon) E3 ubiquitin ligase, linked via a flexible PEG1 spacer to a terminal carboxyl group, facilitating further conjugation to target protein ligands. As part of the 'E3 Ligase Ligand-Linker Conjugate' category, Pomalidomide-PEG1-CO2H plays a central role in the synthesis of bifunctional PROTAC molecules capable of directing ubiquitination and proteasomal degradation of disease-associated proteins. Ideal for academic and pharmaceutical research, this product is suitable for generating customized PROTACs to modulate challenging targets and advance drug discovery programs.
Structure of 2139348-60-8
Quality Assurance
Worldwide Delivery
24/7 Customer Support
Category
E3 Ligase Ligand-Linker Conjugate
Molecular Formula
C18H19N3O7
Molecular Weight
389.36
Appearance
Solid
* For research and manufacturing use only. Not for human or clinical use.
Size
Price
Stock
Quantity
--
$--
In stock
Looking for different specifications? Click to request a custom quote!
Pomalidomide-PEG1-CO2H is a specially designed E3 ligase ligand-linker conjugate used in targeted protein degradation technologies, such as PROTACs (Proteolysis Targeting Chimeras). This compound combines pomalidomide, a cereblon (CRBN) E3 ligase recruiter, with a short polyethylene glycol (PEG1) linker terminated in a carboxylic acid group, enabling flexible conjugation and enhanced solubility. Its strategic structure makes it an essential building block for researchers developing novel PROTAC molecules in drug discovery and chemical biology.
Mechanism
Pomalidomide-PEG1-CO2H operates by leveraging the affinity of pomalidomide for the cereblon (CRBN) E3 ubiquitin ligase. In a typical PROTAC application, this ligand-linker module is covalently conjugated via the terminal carboxylic acid group to a ligand that binds a target protein. The PEG1 linker enhances solubility and provides optimal spatial orientation, bringing the target protein into close proximity to the CRBN E3 ligase machinery. This results in ubiquitination and subsequent proteasomal degradation of the targeted protein, thereby modulating protein levels within the cell.
Applications
Pomalidomide-PEG1-CO2H is widely used in the design and synthesis of custom PROTAC molecules and molecular glues for targeted protein degradation. Its applications include facilitating the development of next-generation therapeutics for cancer, neurodegenerative diseases, and beyond. Researchers utilize this conjugate for SAR (structure-activity relationship) studies, mechanistic evaluation of E3 ligase recruitment, and the exploration of new target proteins as part of the expanding field of targeted protein degradation. Its modular structure also allows for rapid peptide or small-molecule linker optimization during medicinal chemistry campaigns.
• Carboxylic acid functionality enables easy coupling to target ligands or payloads for efficient PROTAC assembly.
• PEG1 linker improves solubility and provides greater flexibility, optimizing spatial orientation in PROTAC design.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
CAS No.: 2139348-60-8
Purity: ≥98%
